A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab ... Sesinando Daval-Santos IV, for collection of data, supervision of research, provision of trial materials ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

In the phase 3 KEYNOTE-006 study (NCT01866319), pembrolizumab (Keytruda) demonstrated sustained survival benefits over ipilimumab (Yervoy) in patients with unresectable stage III or IV melanoma, based ...

COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor ...

Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...

Depending on the chemo drugs your healthcare provider recommends, you may receive chemotherapy intravenously (IV) through a vein or oral (by ... allow immune cells to attack cancer cells. Keytruda ...